HARMANJIT RANDHAWA: Open Payments
NPI 1275158321 · FRESNO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$812 in 39 payments from 12 companies in 2025. Trend: 2023 $406 · 2024 $1,029 · 2025 $812
Food & beverage: $812
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $437 |
| Corcept Therapeutics | 3 | $84 |
| Phathom Pharmaceuticals, Inc. | 4 | $57 |
| GlaxoSmithKline, LLC. | 2 | $41 |
| AstraZeneca Pharmaceuticals LP | 2 | $35 |
| Novo Nordisk Inc | 1 | $31 |
| Otsuka America Pharmaceutical, Inc. | 1 | $30 |
| Exact Sciences Corporation | 1 | $23 |
| PFIZER INC. | 1 | $23 |
| Tandem Diabetes Care, Inc. | 1 | $21 |
Products named: VRAYLAR, UBRELVY, Korlym, VOQUEZNA, QULIPTA, TRELEGY ELLIPTA, CREON, LINZESS.
Industry payments across CA — which companies pay providers there.
